15 Myeloproliferative Neoplasms Clinical Trials in New York, NY (2026)

Q: How do I join a clinical trial in New York?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you.

Recruiting Myeloproliferative Neoplasms Studies in New York

NCT07362225Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include ...

New York, NY5,000 participantsMPN Research Foundation

View Study Details

NCT06034002Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA03...

New York, NYPHASE1290 participantsIncyte Corporation

View Study Details

NCT06093672Recruiting

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients....

New York, NYPHASE3220 participantsItalfarmaco

View Study Details

NCT06313593Recruiting

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms....

New York, NYPHASE1186 participantsIncyte Corporation

View Study Details

NCT07008118Recruiting

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms....

New York, NYPHASE1120 participantsIncyte Corporation

View Study Details

NCT06343805Recruiting

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and chang...

New York, NYPHASE176 participantsAjax Therapeutics, Inc.

View Study Details

NCT06517875Recruiting

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofib...

New York, NYPHASE268 participantsGlaxoSmithKline

View Study Details

NCT05980806Recruiting

A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on ...

New York, NYPHASE258 participantsKaryopharm Therapeutics Inc

View Study Details

NCT06541249Recruiting

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

Low-dose MTX is a widely used, inexpensive, and safe therapy used for decades and is well tolerated by patients with rheumatologic diseases. Recently, it was identified as a type 2 JAK inhibitor. If M...

New York, NYPHASE254 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT06773195Recruiting

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test diffe...

New York, NYPHASE137 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05371964Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the s...

New York, NYPHASE136 participantsGeron Corporation

View Study Details

NCT05423691Recruiting

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib...

New York, NYPHASE124 participantsCellenkos, Inc.

View Study Details

NCT05714072Recruiting

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe and effective treatment for people with primary or post-polycythemia vera/essential thrombocythemia myelofibr...

New York, NYPHASE118 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05025488Recruiting

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 m...

New York, NYPHASE110 participantsMarina Kremyanskaya

View Study Details

NCT05835466Recruiting

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thro...

New York, NYPHASE210 participantsIcahn School of Medicine at Mount Sinai

View Study Details

About Myeloproliferative Neoplasms Clinical Trials in New York

Myeloproliferative neoplasms (MPNs) are blood cancers in which the bone marrow overproduces red blood cells, platelets, or white blood cells. Types include polycythemia vera, essential thrombocythemia, and myelofibrosis. Treatment depends on the specific type and risk factors.

There are currently 15 myeloproliferative neoplasms clinical trials recruiting participants in New York, NY. These studies are seeking a combined 6,207 participants. Research is being sponsored by MPN Research Foundation, Incyte Corporation, Italfarmaco and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myeloproliferative Neoplasms Clinical Trials in New York — FAQ

Are there myeloproliferative neoplasms clinical trials in New York?

Yes, there are 15 myeloproliferative neoplasms clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New York?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.

Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.

What myeloproliferative neoplasms treatments are being tested?

The 15 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for myeloproliferative neoplasms.

Data updated July 16, 2026 from ClinicalTrials.gov